The impact of mass drug administration and long-lasting insecticidal net distribution on Wuchereria bancrofti infection in humans and mosquitoes: an observational study in northern Uganda by Ashton, Ruth A et al.
RESEARCH Open Access
The impact of mass drug administration and
long-lasting insecticidal net distribution on
Wuchereria bancrofti infection in humans and
mosquitoes: an observational study in northern
Uganda
Ruth A Ashton
1,2*, Daniel J Kyabayinze
3, Tom Opio
4, Anna Auma
5, Tansy Edwards
6, Gabriel Matwale
5,
Ambrose Onapa
7, Simon Brooker
2,8 and Jan H Kolaczinski
1,2
Abstract
Background: Lymphatic filariasis (LF) in Uganda is caused by Wuchereria bancrofti and transmitted by
anopheline mosquitoes. The mainstay of elimination has been annual mass drug administration (MDA) with
ivermectin and albendazole, targeted to endemic districts, but has been sporadic and incomplete in coverage.
Vector control could potentially contribute to reducing W. bancrofti transmission, speeding up progress towards
elimination. To establish whether the use of long-lasting insecticidal nets (LLINs) can contribute towards
reducing transmission of W. bancrofti in a setting with ongoing MDA, a study was conducted in an area of
Uganda highly endemic for both LF and malaria. Baseline parasitological and entomological assessments were
conducted in 2007, followed by high-coverage LLIN distribution. Net use and entomological surveys were
carried out after one year, and final parasitological and entomological evaluations were conducted in 2010.
Three rounds of MDA had taken place before the study commenced, with a further three rounds completed
during the course of the study.
Results: In 2007, rapid mapping indicated 22.3% of schoolchildren were W. bancrofti antigen positive, and a
baseline survey during the same year found age-adjusted microfilaraemia prevalence was 3.7% (95% confidence
interval (CI): 2.6-5.3%). In 2010, age-adjusted microfilaraemia prevalence had fallen to 0.4%, while antigenaemia
rates were 0.2% in children < 5 years and 6.0% in ≥ 5 years. In 2010, universal coverage of mosquito nets in a
household was found to be protective against W. bancrofti antigen (odds ratio = 0.44, 95% CI: 0.22-0.89).
Prevalence of W. bancrofti larvae in anopheline mosquitoes had decreased significantly between the 2007 and
2010 surveys, but there was an apparent increase in vector densities.
Conclusion: A marked reduction in W. bancrofti infection and infectivity in humans was observed in the study
area, where both MDA and LLINs were used to reduce transmission. The extent to which LLINs contributed to this
decline is equivocal, however. Further work investigating the impact of vector control on anopheline-transmitted
LF in an endemic area not benefitting from MDA would be valuable to determine the effect of such interventions
on their own.
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Lymphatic filariasis (LF) is a major cause of acute and
chronic morbidity of humans living in the tropics. The
disease is caused by infection with the parasitic worm
Wuchereria bancrofti in Africa (Brugia malayi and B.
timori in Asia-Pacific) and is transmitted by Anopheles,
Culex, Aedes and Mansoni mosquitoes [1,2]. Infection
with the parasite leads to disabling lymphoedema,
hydrocoele and acute adenolymphangitis (ADL) [3,4], as
well as less-evident morbidity such as adenopathy, lym-
phangitis, haematuria and proteinuria [3,5,6]. LF is cur-
rently endemic in 81 countries and, while it has been
largely controlled in much of the Pacific and China,
remains an important health problem in India and sub-
Saharan Africa [7].
LF is targeted for elimination by the year 2020 [8],
with the primary tool to achieve this ambitious goal
being mass drug administration (MDA) of albendazole
plus either ivermectin or diethylcarbamazine citrate
(DEC) to the at-risk population [9]. Regular MDA
reduces microfilaria (mf) loads and hence LF trans-
mission, but has little macrofilaricidal effect [10].
MDA therefore needs to continue until adult worms
lodged in human hosts die naturally or cease to be
fecund (mf producing), which has been estimated to
take about five years [11]. Maintaining high coverage
of MDA over several years is challenging, particularly
in resource constraint settings [12], and has to pro-
ceed with caution or not at all in areas where the
parasitic worm Loa loa is prevalent, due to the
increased risk of severe adverse events [9,13]. Due to
these limitations of MDA, vector control is increas-
ingly being considered as a complementary tool for
LF elimination [14-16], particularly in locations where
Anopheles mosquitoes are the vector and malaria is
co-endemic.
The naturally inefficient transmission of W. bancrofti,
as well as the process of facilitation, whereby develop-
ment of infective L3 larvae becomes more efficient with
increased numbers of W. bancrofti ingested by the mos-
quito, but consequently reduces mosquito survival
[17,18], make vector control particularly attractive for
LF control. Perhaps the key factor supporting use of
vector control against LF is the ongoing scale-up in
long-lasting insecticidal net (LLIN) coverage against
malaria in sub-Saharan Africa [19]. W. bancrofti is
transmitted by Anopheles across west Africa and in
some rural areas of east Africa. In these areas co-ende-
mic for malaria and Anopheles-transmitted W. bancrofti,
use of LLINs has the potential to successfully reduce
transmission of both parasites, but despite promising
results from pilot studies indicating potential benefits of
LLINs against LF (Table 1) [20-23], longitudinal data to
this effect are few [24].
LF in Uganda is caused by W. bancrofti and trans-
mitted by Anopheles gambiae s.l.a n dAn. funestus mos-
quitoes [25]; the disease is largely concentrated in the
north of the country [26]. MDA with albendazole and
ivermectin commenced in 2002 [12], but has been
sporadic and incomplete [27]. Since 2007, concerted
efforts have been undertaken to expand MDA coverage
to target 7.2 million people [28]. Coverage of malaria-
endemic areas with LLINs has been steadily increasing
[29] and the goal of the national policy has recently
been amended to focus on universal coverage (defined
as one net for every two people) [30].
Table 1 Summary of current evidence of describing impact mosquito nets on W. bancrofti transmission by Anopheles
Key findings Vector Location Reference
LLIN distribution targeted to pregnant women and < 5s resulted in reduction of 60% in vector
population
Universal LLIN coverage resulted in 90% decline in vector population
Both LLIN strategies resulted in significant reduction in proportion of mosquitoes with any W.
bancrofti larval stage
Anopheles spp. Nigeria [24]
Use of insecticide-treated net (ITN) reduced density of indoor resting An. gambiae s.l. and An.
funestus
An. funestus and An. gambiae showed slight switch to animal feeding after ITN adoption, Cx.
quinquefasciatus switch to majority animal feeding
Vector potential reduced by ≥ 97% for Cx. quinquefasciatus, An. gambiae and An. funestus
An. gambiae,
An. funestus,
Cx. quinquefasciatus
Kenya [20]
Introduction of ITNs resulted in reduction of overall mosquito density by 22.6%
Annual transmission potential was reduced by 92%
Annual infective biting rate was reduced by 95%
An. funestus,
An. gambiae,
Cx. quinquefasciatus
Kenya [21]
In case-control study, individuals using untreated mosquito net had higher odds of LF than those
using ITNs
Not specified Cambodia [22]
Use of untreated mosquito nets was associated with reduced odds of W. bancrofti antigenaemia
and microfilaraemia
Individuals using untreated mosquito nets also had lower odds of hydrocoele than non-users
An. farauti,
An. punctulatus,
Cx. annulirostris,
Cx. quinquefasciatus
Papua New
Guinea
[23]
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whether large-scale distribution of LLINs could contri-
bute towards the MDA-based transmission control of
LF. Specifically, this included estimating prevalence of
W. bancrofti infection pre- and post-intervention with
LLIN distribution, and investigating associations
between W. bancrofti infection and various indicators of
ownership and use of mosquito nets.
Methods
Site selection
In May 2007, rapid LF mapping was conducted using
immunochromotographic tests (ICT; BinaxNOW Filaria-
sis, Binax Inc., Scarborough, ME) to detect W. bancrofti
antigen in school children, according to World Health
Organization (WHO) recommendations [9]. Children
from six primary schools in Lira, Amolatar and Dokolo
districts, north of lake Kyoga, were tested (Figure 1).
These districts had previously been identified as highly
endemic for W. bancrofti [26]. Selection of schools for
rapid mapping was based on a sampling grid with 50
km between each school [9,31], as well as anecdotal
reports of high infection levels provided by the District
Health Offices. At each school, 175 children aged
between six and 16 years were randomly selected to
provide a finger prick blood sample for analysis by ICT.
The school in Adeknino parish, Dokolo district, had
the highest prevalence of W. bancrofti antigen (22.3%,
95% confidence interval (CI) 16.4-29.2%). Seven adjacent
villages in Adeknino parish were therefore selected as
the study area for detailed parasitological surveys, which
was deemed sufficient to reach the calculated sample
size.
Study design
A pre- and post-intervention observational study was
conducted to examine the impact of MDA and mass
distribution of LLINs. A timeline of study activities,
including delivery of interventions, is shown in Figure 2.
Parasitological surveys to determine W. bancrofti micro-
filariaemia were conducted in July 2007 and July 2010.
Rates of W. bancrofti antigenaemia were also evaluated
in 2010 using ICTs. The survey in July 2008 did not
include collection of blood samples. During all three
surveys, three key mosquito net variables were evalu-
ated: i) individual use of a net on the previous night, ii)
Figure 1 Results of rapid mapping at six primary schools in Northern Uganda in May 2007: prevalence of W. bancrofti antigen in
children aged 6-16, determined by immunochromatographic test (Binax Now filariasis, Portland, ME).
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Page 3 of 13number of nets in the household, and iii) universal cov-
erage with nets in the household. In addition, Anopheles
mosquitoes were caught and dissected during each sur-
vey, to estimate the prevalence of W. bancrofti infection
and infectivity in the vector population. MDA with
albendazole and ivermectin were delivered in October
2007, October 2008 and November 2009. Four thousand
LLINs were distributed to all 16 villages in Adeknino
Parish in January 2008.
Baseline survey
A population census in the study area was carried out in
July 2007 using a standardised questionnaire. All house-
holds in the seven villages were visited; verbal consent for
inclusion was obtained after explaining the purpose of the
interview. Basic demographic details of household mem-
bers and key socioeconomic characteristics were recorded,
as well as information on mosquito net ownership and
use. Mosquito net ownership and condition was verified
by visual inspection. In order to capture the protection
conferred by LLINs in different age groups, two indivi-
duals, one below and one above five years of age (with no
upper age limit), were randomly selected from each house-
hold by roll of a die, and requested to provide a night-time
blood sample for detection of W. bancrofti microfilaria.
Upon arrival at a central location between 9 pm and 1
am, participants were informed of procedures and
requested to provide verbal consent. Participants were
examined by a medical doctor for signs of elephantiasis
and hydrocoele according to standard WHO definitions
[32]; the same doctor performed all clinical examina-
tions. A single finger-prick blood sample was used to
prepare a thick blood smear, and to collect 100 μl blood
using a heparin-coated capillary tube that was added to
900 μl 3% acetic acid for microfilaria detection by
counting chamber technique.
LLIN distribution follow-up survey
A follow-up survey was conducted in July 2008, six
months after distribution of 4,000 LLINs to the 16 vil-
lages in the study parish. Forty households from each
of the seven study villages were selected by random
walk, beginning from the centre of the village where a
pen was spun to select the direction. The head of
household was interviewed using a standardised ques-
tionnaire to determine basic household characteristics,
socio-economic indicators and use of mosquito nets by
household members. Condition and location of all
mosquito nets in the household were verified by visual
inspection.
Figure 2 Flowchart describing study activities 2007-2010 and interventions conducted at the study site including mass drug
administration with ivermectin and albendazole (MDA) against W. bancrofti, and distribution of long-lasting insecticide-treated
mosquito nets (LLINs).
1 The school with the highest W. bancrofti prevalence as determined by ICT, was in Adeknino Parish in Dokolo. A group
of seven adjacent villages in this parish were selected as the study site.
2 MDA population coverage calculated as number of individuals
receiving albendazole and ivermectin, divided by the projected total population of the sub-county which includes Adeknino Parish.
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Three years post-baseline (July 2010), a final population
census and parasitological survey was conducted. Since
the prevalence of W. bancrofti mf found at baseline was
lower than assumed in the sample size calculation, the
sampling strategy was adjusted to maximise power to
determine a change in mf prevalence. It was decided to
over-sample children under five years during the parasi-
tological survey to generate sufficient data to allow esti-
mation of recent transmission. Therefore, all children
under five years of age in the study villages were
included in the survey. Furthermore, a stepwise diagnos-
tic approach was taken, with ICTs being used as the
first-line tool, followed by night bleeds only for ICT-
positive individuals. This approach took advantage of
the high sensitivity of ICTs for detection of W. bancrofti
infection, hence minimizing the logistical difficulties
involved in conducting large numbers of night bleeds.
All households in study villages were visited and a
standardised questionnaire carried out, similar to the
questionnaire used at baseline. At all households, a fin-
ger-prick blood sample was collected from any child
below five years of age for preparation of ICT test. At
every third household visited, household members of all
ages were invited to be included in blood sampling. Any
individual with a positive ICT result was requested to
attend night-time blood sampling between 9 pm and 1
am, where a thick blood film was prepared and 100 μl
blood stored in 900 μl 3% acetic acid.
Entomological surveillance
Entomological surveillance was conducted at the same
time as household surveys in 2007, 2008 and 2010. A
CDC light trap was set next to a sleeping place in ten
randomly selected consenting households at dusk each
day. Untreated mosquito nets were provided for all
sleeping places in buildings where a light trap was set,
and any hanging insecticide-treated nets removed while
the traps were in use. Traps were collected at dawn the
following day. Mosquitoes were anaesthetised, sorted by
sex and species, and female Anopheles were dissected
and mounted on slides. Light traps were set in ten new
households every night until the target sample size of
Anopheles was reached: 1,000 in 2007 and 2008, and
3,000 in 2010.
Microscopy
Thick blood films were air-dried and stained with
Giemsa, then examined for presence of W. bancrofti
microfilaria. Acetic acid blood samples were examined
for W. bancrofti by counting chamber method, and the
number of microfilaria recorded and converted to
microfilaria per ml of peripheral blood (mf/ml) [33].
Dissected mosquitoes mounted on slides were fixed
with methanol, then stained using haematoxylin stain
and examined for filarial species. The species and
number of larvae, developmental stage and location
were recorded.
Sample size
Sample size calculations were conducted in Stata 9.2
(Stata Corporation, College Station, TX) using the
‘sampsi’ command, aiming at 80% power and a signifi-
cance level of 5%, exploring a variety of scenarios with
estimated W. bancrofti prevalence ranging from 10-18%
and protective efficacy of LLINs from 27-55%. These
calculations indicated that 1,000 individuals would need
to be sampled at each time-point to determine whether
t h e r ew a sas t a t i s t i c a ld i f f e r e n c ei np r e v a l e n c eo fW.
bancrofti infection between individuals protected by a
LLIN and those individuals unprotected. No allowances
for inter-village variation were made, since it was
assumed that the population and infection risk in the
selected villages would be similar. It was not possible to
conduct the study in a single village of Adeknino parish
due to small village populations; therefore seven adja-
cent villages were included.
Sample size for entomological surveys was calculated
assuming 6% of dissected mosquitoes would be infected
[25], and a reduction of 50% in proportion infected
would be seen, with 80% power and significance level of
5%. However, since prevalence of infection was found to
be lower than expected at baseline, the sample size was
increased in the final follow-up survey to the maximum
number logistically feasible to collect and dissect.
Analysis
Data were entered into a Microsoft Access database
(Microsoft corporation, Seattle, WA) subject to valida-
tion checks. Statistical analysis was carried out in Stata
9.2. Principal component analysis was used to create a
wealth index for each household that adequately sum-
marised socio-economic factors; household were then
divided into quintiles according to this index [34].
Mosquito net use and ownership were measured and
analysed in the following ways: i) sleeping under a net
on the evening prior to the survey (categorical: no net
used, slept under untreated net, slept under LLIN); ii)
universal net coverage in household, a binary variable
measured as one or more nets for every two individuals,
iii) number of nets per household (discrete). To quanti-
tatively assess the condition of existing nets, a propor-
tional hole index was calculated, where number and size
of holes in each net are summarised. This is calculated
as the number of finger-sized holes, plus number of fist-
sized holes multiplied by nine, plus number of head-
sized holes multiplied by 56. A proportional hole index
of < 25 was categorised as good, 25-299 as moderate,
Ashton et al. Parasites & Vectors 2011, 4:134
http://www.parasitesandvectors.com/content/4/1/134
Page 5 of 13and ≥ 300 as poor condition (A. Kilian, personal
communication).
Coverage data for each round of MDA were provided
by central records of the national LF control programme
(2002-2006 data) and Dokolo district health office (data
for 2007 onwards). Coverage was defined as number of
individuals receiving ivermectin and albendazole, divided
by the projected total population as calculated by the
Uganda Bureau of Statistics. Coverage data for 2007-
2009 are presented at the sub-county level, while data
for 2002, 2003 and 2005 are presented as total for the
former Lira district, which includes the current Lira,
Dokolo and Amolatar districts.
Unadjusted prevalence of W. bancrofti mf is presented
for children under five years and all those aged five and
older from 2007 and 2010 surveys, as well as W. ban-
crofti antigen prevalence from 2010. Exploratory analysis
using generalised linear and latent mixed models
(GLLAMM) found little evidence for any effect of clus-
tering of W. bancrofti mf or antigen by village. Simple
generalised linear models (GLM) were therefore used to
produce age-adjusted prevalence estimates and corre-
sponding 95% CI for W. bancrofti mf in 2007 and 2010,
as well as W. bancrofti antigen in 2010. Each GLM was
tested with both linear and categorical (ten-year bins,
then all ≥ 50) age variables to determine any departure
from linear trend. All the GLM included sex ap r i o r i ,
and were calculated using robust standard error esti-
mates. Chi squared test was used to compare crude and
adjusted prevalence of infection between baseline and
follow-up.
To investigate associations between each infection
outcome (W. bancrofti antigen and W. bancrofti mf) and
net use and ownership measures at three years post-
baseline across all ages, logistic regression was first used
to test each net ownership and use measure and socio-
demographic characteristics in univariate analyses. The
net variables considered key primary exposures for sepa-
rate multivariate models were a categorical variable of
sleeping under a net on the previous night (did not
sleep under a net, slept under untreated net, slept under
LLIN) and universal coverage with any net type in the
household. In multivariable modelling, age category, sex
and village-level baseline W. bancrofti mf prevalence
among those aged five and older were included in all
models a priori. A final model was obtained using a for-
ward stepwise approach with inclusion criteria of p <
0.1, based on results of likelihood ratio tests (LRT), test-
ing covariates with strongest univariate association with
outcome first. Robust standard errors were applied to
final multivariate models, to adjust for potential underly-
ing heterogeneities in the data and therefore provide a
conservative estimate of association between net indica-
tors and outcome.
Density of Anopheles mosquitoes was described using
the monthly biting rate (MBR) for July, calculated as:
(total mosquitoes caught*31)/(number of traps*number
of nights traps set).
The MBR assumes that the number of mosquitoes
c a u g h ti nal i g h tt r a pi se q u i v a l e n tt ot h a tw h i c hw o u l d
be collected by human landing catches. Monthly trans-
mission potential (MTP) describes the mean number of
W. bancrofti infectious bites received during the month,
calculated as: (MBR*number mosquitoes with L3 infec-
tion)/total mosquitoes caught. The proportion of all
mosquitoes carrying any W. bancrofti larval stage is also
presented.
Ethical considerations
The Uganda National Council for Science and Technol-
ogy approved the study protocol (HS 271). Clearance to
conduct the surveys was obtained from the local autho-
rities. Verbal informed consent to conduct interviews
was received from head of household and recorded on
questionnaires. Verbal consent was requested from all
adults and parents or guardians of minors for collection
of blood samples, with approval given/refused recorded
on consent forms. Individuals that declined to partici-
pate were excluded from the study. Verbal informed
consent was gained from head of household before set-
ting light traps, and untreated mosquito nets were pro-
vided for all sleeping places in each structure where
traps were set.
Results
Study population
The number of households and individuals interviewed
and providing blood samples in the 2007, 2008 and
2010 surveys are detailed in Figure 2. In 2010, 43/48
(90%) of individuals with a positive ICT result provided
a night bleed sample. In the 2007 and 2010 surveys,
individuals who had been resident in the sub-county for
less than two years were excluded (n = 144 in 2007, n =
169 in 2010), while families that had been resident in
the village for fewer than seven months, the time since
the LLIN distribution, were excluded from the 2008 sur-
vey (n = 6).
Mosquito net ownership and use
In 2007, households had a mean number of 1.0 nets,
with only 14.5% of households found to have sufficient
nets to allocate one to every two people (defined as uni-
versal coverage). Of all nets examined in 2007, 50.5%
were LLINs and 57.9% were in good condition. Six
months after the LLIN distribution in 2008, households
had an average of 2.8 nets, and 55.5% had achieved uni-
versal coverage. Unsurprisingly, 94.7% of nets were in
good condition and 91.0% of all nets were in use
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bution. By 2010, net coverage and condition had dete-
riorated to a mean of 2.0 nets per household, with only
38.1% households being in the universal coverage cate-
gory. Only 36.8% of nets remained in good condition.
The main reason given by individuals for discarding
their nets was that they had developed holes.
At baseline in 2007, 43.3% of all individuals reported
sleeping under a mosquito net on the previous night.
After the LLIN distribution, this rose to 81.9% of people
sleeping under a mosquito net, but in 2010 only 60.2%
of those surveyed reported using a net during the pre-
vious night. Summary net use stratified by age and net
type are presented in Table 2.
Mass drug administration
MDA with ivermectin and albendazole began in Uganda
2002, targeting two districts (including the study site)
o u to ft h et o t a l2 2L Fe n d e m i cd i s t r i c t s .M D Aw a s
scaled up gradually in the following years, but no MDA
took place during several years due to lack of opera-
tional funds [27]. Annual MDA has routinely taken
place since 2007 (Figure 2), usually in October each year
during Child Health Days Plus, but occasionally delayed
due to financial or logistical constraints. The villages in
the study had received six rounds of MDA by the end
of the study; in 2002, 2004-5 and 2007-9, with reported
population coverage between 49.9% and 80.9%.
W. bancrofti infection in humans
In the baseline survey conducted in all seven study vil-
lages, the sex- and age-adjusted (referred to as age-
adjusted from this point) W. bancrofti mf prevalence
was 3.7%. Crude mf prevalence in children under five
years was 0.9%, and 6.8% in those aged five years and
above. The geometric mean mf intensity was 165 mf/ml
(95% CI 98-277 mf/ml, Table 3).
Acute adenolymphangitis (ADL) was diagnosed in
1.2% individuals of all ages examined at baseline. A
further 1.2% had some form of elephantiasis: the leg was
most commonly affected, but single cases in the arm,
breast and scrotum were identified. Six cases of hydro-
coele were diagnosed (1.5% males of all ages), with four
having previously received corrective surgery.
The age-adjusted W. bancrofti antigen prevalence in
2010 was 2.1% (Table 3). The unadjusted prevalence of
W. bancrofti antigen in children under five years was
0.2%, and 6.0% among those aged five and older (Table
3). The youngest ICT positive individual in 2010 was
four years old. Assuming that the ICT provides a sensi-
tive marker of infection, the age-adjusted mf prevalence
was 0.4%, crude prevalence being 0% in children under
five and 0.8% in those five and older. Geometric mean
mf intensity among individuals with mf-positive night-
bleed sample was 80 mf/ml (95% CI 18-343 mf/ml).
There is strong evidence for a reduction in mf preva-
lence from 2007 to 2010, both among children under
five years (p = 0.034) and in those aged five and above
(p < 0.001).
Due to the small number of individuals with mf in
2010, risk factors were not evaluated for mf, but only
for W. bancrofti antigen. Univariate risk factors for W.
bancrofti antigen are detailed in Table 4.
Two multivariate models were created; the first
included individual use and type of mosquito nets, the
second explored impact of universal net coverage in a
Table 2 Key indicators of mosquito net and LLIN ownership and use over the study period
2007 2008 2010
Number of households assessed 552 281 591
Number of individuals assessed 3072 1569 3334
Mean nets per household 1.0 (0.9-1.1) 2.8 (2.7-2.9) 2.0 (1.9-2.1)
Households with universal net coverage
1 14.5 (11.7-17.7) 55.5 (49.5-61.4) 38.1 (34.1-42.1)
Percent of nets found hanging or tied over sleeping place 93.1 (90.6-95.1) 90.6 (88.2-92.6) 83.5 (81.3-85.6)
Percent of nets being LLINs 50.5 (45.6-55.3) 95.3 (93.6-96.7) 86.7 (84.7-88.6)
Mean LLINs per household 0.5 (0.4-0.5) 2.5 (2.4-2.7) 1.7 (1.6-1.8)
Net use on previous night, among < 5 years:
Did not sleep under a net 64.6 (60.8-68.4) 11.4 (8.2-15.4) 27.1 (23.7-30.8)
Slept under untreated net 14.6 (12.0-17.7) 8.3 (5.6-11.9) 17.9 (15.0-21.2)
Slept under LLIN 20.7 (17.6-24.1) 80.2 (75.5-84.4) 54.9 (50.9-58.9)
Net use on previous night, among ≥ 5 years:
Did not sleep under a net 72.5 (70.7-74.3) 19.6 (17.4-21.9) 42.8 (40.9-44.7)
Slept under untreated net 14.8 (13.4-16.3) 8.6 (7.1-10.3) 9.0 (7.9-10.1)
Slept under LLIN 12.7 (11.4-14.1) 71.8 (69.2-74.3) 48.2 (46.3-50.1)
Data are percent (exact binomial 95% confidence intervals) unless otherwise stated.
1One mosquito net for every two people in the household
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dual use of untreated nets or LLINs and W. bancrofti
antigen (data not shown). Universal household net cov-
e r a g ew a sf o u n dt ob ep r o t e c t i v ea g a i n s tW. bancrofti
infection in the final multivariate model (OR = 0.44,
95% CI, 0.22-0.89, Table 5).
W. bancrofti infection in mosquitoes
In 2007, 1,168 female Anopheles were caught and dis-
sected. A total of nine were found to be carrying W.
bancrofti larvae (0.77%, 95% CI: 0.35-1.46), with only
two being infective L3 stages (0.17%, 95% CI: 0.02-0.62).
Data specifying number of Anopheles caught per trap
per night were not recorded in 2007, consequently, it
was not possible to calculate the monthly biting rate
and monthly transmission potential for the study period
(July).
A total of 1,278 female Anopheles were caught and
dissected in 2008, 467 An. gambiae and 811 An. funes-
tus, and the estimated biting rate for the month of July
was 304 bites/person/month. Prevalence of W. bancrofti
in these mosquitoes was 1.8% (95% CI: 1.1-2.7), with
prevalence in An. gambiae 2.4% and An. funestus 1.5%.
Only one An. gambiae mosquito was found to have L3
W. bancrofti stages, giving an overall prevalence of
infectivity in the Anopheles population of 0.08% (95%
CI: 0.002-0.4), the monthly transmission potential for
July was calculated to be 0.24 infectious bites/person/
month.
In 2010, 2,959 female Anopheles were dissected, 828
An. gambiae and 2,131 An. funestus, which translated
into a monthly biting rate of 540 bites/person/month
for July. Three mosquitoes (0.1%, 95% CI: 0.02-0.3) were
found to be infected with W. bancrofti larvae, all of
which were L1 stage. Since no mosquito was found to
have L3 W. bancrofti, the monthly transmission poten-
tial was zero. Mean larval count among infected mos-
quitoes was 2.0.
The proportion of mosquitoes infected with any stage
of W. bancrofti larvae declined between 2007 and 2010
(Fisher’s exact p = 0.001). Although there appeared to
be a decrease in the proportion of mosquitoes with the
infective L3 stage, this was not statistically significant
(Fisher’s exact p = 0.080). The biting rate increased
from 2008 to 2010, while the transmission potential
declined.
Discussion
T h ea i mo ft h ec u r r e n ts t u d yw a st oi n v e s t i g a t et h e
impact of MDA on LF transmission where large-scale
distribution of LLINs had been implemented. Over the
three year follow-up period, it was found that coverage
and use of LLINs increased immediately after a mos-
quito net distribution campaign, but declined over the
next two years in the absence of access to replacement
nets by the population. W. bancrofti mf prevalence
declined sharply over the course of the study, to below
1%. Universal coverage of mosquito nets in a household
was found to be protective against human W. bancrofti
infection (based on antigen detection) in multivariate
modelling. However, although there was a reduction in
W. bancrofti infection prevalence in mosquitoes, there
Table 3 Key indicators of W. bancrofti in human population over the study period.
2007 2010
Number of individuals providing blood samples 896 1304
Number of blood samples from < 5 yrs (%) 348 (38.9) 521 (40.0)
Crude % prevalence estimates
1
W. bancrofti antigen in < 5 years - 0.2 (0.01-1.1)
W. bancrofti antigen in ≥ 5 years - 6.0 (4.4-7.9)
W. bancrofti mf in < 5 years
2 0.9 (0.2-2.5) 0.0 (0.0-0.7)
3
W. bancrofti mf in ≥ 5 years
2 6.8 (4.8-9.3) 0.8 (0.3-1.7)
W. bancrofti geometric mean (range) 165 (10-3,790) 80 (10-260)
Lymphoedema/elephantiasis 1.2 (0.6-2.2) -
Hydrocoele, amongst males 1.5 (0.6-3.3) -
Acute adenolymphangitis 1.2 (0.6-2.2) -
Adjusted % prevalence estimates
4
W. bancrofti antigen - 2.1 (1.2-3.7)
W. bancrofti mf 3.7 (2.6-5.3) 0.4 (0.2-1.0)
1 With exact binomial 95% confidence interval
2 All ICT negative samples assumed to be mf negative
3 One-sided test, 97.5 confidence interval
4 Estimated using generalised linear models, with robust 95% confidence intervals. All models are also adjusted for sex. Age was included as a linear variable in
W. bancrofti mf 2007 and 2010 models. Age was included as a categorical variable with 10 year bins and grouping all ≥ 50 years in W. bancrofti antigen 2010
model.
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Page 8 of 13Table 4 Univariate associations for W. bancrofti infection in 2010, with 95% confidence intervals (CI).
N individuals n (%) infected OR 95% CI Wald p
Sex (female) 701 23 (3.3) 0.78 0.44-1.39 0.403
Age category
1:
< 10 754 2 (0.3) 1.00 - -
10-19 241 14 (5.8) 23.3 5.10-106.0 < 0.001
20-29 108 12 (11.1) 47.1 9.73-228.3 < 0.001
30-39 98 10 (10.2) 42.8 8.70-210.9 < 0.001
40-49 49 7 (14.3) 62.8 11.6-340.9 < 0.001
≥ 50 52 3 (5.8) 23.1 3.7-145.5 < 0.001
Socio-economic status
2:
Poorest 261 11 (4.2) 1.00 - -
2
nd 246 10 (4.1) 0.96 0.40-2.31 0.933
3
rd 257 8 (3.1) 0.73 0.29-1.85 0.505
4
th 271 5 (1.9) 0.43 0.15-1.25 0.110
Least poor 261 14 (5.4) 1.29 0.57-2.90 0.539
Village:
Adyangoto B 174 12 (6.9) 1.46 0.64-3.34 0.364
Akabi 142 9 (6.3) 1.34 0.55-3.26 0.522
Okwor 150 4 (2.7) 0.54 0.17-1.71 0.289
Aridi 181 6 (3.3) 0.68 0.25-1.84 0.442
Alwar 226 1 (0.4) 0.09 0.01-0.69 0.004
Acapii 182 4 (2.2) 0.44 0.14-1.40 0.156
Adyangoto A
3 249 12 (4.8) 1.00 - -
Household size
4: 1304 48 (3.7) 0.99 0.88-1.10 0.792
Main material of walls:
Mud/dung 802 30 (3.7) 1.00 - -
Brick 499 18 (3.6) 0.96 0.53-1.75 0.901
Main material of roof:
Grass thatch 1007 36 (3.6) 1.00 - -
Iron sheet 297 12 (4.0) 1.14 0.58-2.21 0.708
Toilet facilities:
None 200 11 (5.5) 1.00 - -
Pit latrine 1090 36 (3.3) 0.59 0.29-1.17 0.128
Education of head of household:
None 131 5 (3.8) 1.00 - -
Primary 982 40 (4.1) 1.07 0.41-2.76 0.889
Secondary or higher 190 2 (1.1) 0.27 0.05-1.42 0.096
Number nets in household (linear) 1304 48 (3.7) 1.05 0.79-1.40 0.748
Sleeping under net on previous night:
Not sleeping under net 390 15 (3.9) 1.00 - -
Sleeping under non-LLIN 204 12 (5.9) 1.56 0.72-3.41 0.258
Sleeping under LLIN 710 21 (3.0) 0.76 0.39-1.50 0.428
Universal net coverage in household
5 350 8 (2.3) 0.53 0.25-1.15 0.110
Proportion of nets in household being LLINs 1304 48 (3.7) 0.99 0.98-1.00 0.008
Proportion of nets in household found hanging/tied over bed/mat 1304 48 (3.7) 0.99 0.98-1.00 0.105
1 Initial categories of < 5 and 5-9 were found to be statistically similar, therefore combined into a single reference category;
2 Socio-economic status estimated using principal component analysis based on ownership of key household assets [34];
3 Adyangoto A village had largest denominator, therefore selected as reference category;
4 Linear data is better fit for associations with infection than household size divided into quartiles;
5 Universal coverage defined as households with at least one net for every two people in the household.
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Page 9 of 13was an apparent increase in vector densities and
monthly biting rates, suggesting there was limited pro-
tection from bites by Anopheles mosquitoes. This could
suggest that the reduction in human W. bancrofti infec-
tion was primarily due to the MDA. Evidence from
Papua New Guinea showed that one round of treatment
with DEC alone can reduce mosquito infection levels
[16]. Precisely determining the individual contributions
of MDA and regular LLIN use to the observed reduc-
tion in W. bancrofti prevalence and transmission is,
however, difficult due to inability to include a control
group in the study design or adopt a factorial study
design as withholding known efficacious interventions
would have been unethical.
The impact of MDA in reducing population levels of
W. bancrofti has been well documented [35-37], with a
combination of ivermectin and albendazole appearing to
give a faster but shorter-lived reduction in microfilaria
rates than DEC and albendazole [38]. While a study in
Kenya has demonstrated the reductions in infection
levels can be maintained even when some rounds of
MDA are missed [39], there is evidence for a waning
effect of MDA after multiple rounds of treatment,
resulting in residual low levels of infection in the popu-
lation [37]. This decrease in effect of MDA after numer-
ous rounds may be a result of incomplete coverage of
the population, or the inadequate macrofilaricidal effect
of drug combinations used. Other studies have shown
that mosquito nets (both insecticide-treated and
untreated) can reduce LF vector density and infectivity,
hence making a significant contribution towards pre-
venting LF transmission [20-24]. The most salient exam-
ple of LF vector control comes from indoor residual
spraying with DDT conducted at large-scale as part of
malaria elimination efforts during the 1960s and 1970s.
Vector control by means of this tool is thought to have
brought about elimination of W. bancrofti from the
Solomon Islands, where An. punctualis was the main
vector [40]. In that setting, W. bancrofti was eliminated
in the absence of MDA, purely as a collateral benefit of
the ultimately unsuccessful malaria elimination activities.
This has parallels with the current scale-up of owner-
ship and use of LLINs in malaria endemic countries,
which will likely impact on other mosquito-borne infec-
tions including LF. There remains a need for further
evidence to establish the effectiveness of LLINs alone
against LF, with promising results emerging from a
study in a L. loa-endemic area of Nigeria [24], where
MDA cannot be implemented and LLINs are therefore
the primary control strategy.
Universal coverage with mosquito nets in a household
was found to be the most important indicator of net
ownership and use in this study, with a protective effect
against W. bancrofti infection remaining in multivariate
models. This indicator can be considered as an approxi-
mation to a household having a mosquito net for every
sleeping space, although this was not measured directly
in the current study. In addition to a household owning
sufficient nets to cover all individuals, these nets must
of course be in use. Throughout the study, a high pro-
portion of all nets were found hanging or tied up in
households, rather than being stored. In the current
data, therefore, universal coverage can be assumed to
mean that not only does a household own sufficient
nets for all, but that all these nets are in regular use.
The finding that mosquito net use on the night before
Table 5 Final multivariate associations between universal net coverage and W. bancrofti antigen in 2010, including all
covariates retained in final models with 95% confidence intervals (CI).
W. bancrofti (antigen)
OR 95% CI Wald p
Universal net coverage
1 0.44 0.22-0.89 0.022
Sex (female) 0.49 0.21-1.12 0.092
Age 10-19 years 27.56 6.22-121.92 < 0.001
Age 20-29 years 71.54 12.33-415.13 < 0.001
Age 30-39 years 49.07 12.37-194.66 < 0.001
Age 40-49 years 70.69 23.03-216.97 < 0.001
Age ≥ 50 years 26.51 2.62-268.26 0.005
Baseline infection prevalence in ≥ 5 yrs, by village
2 1.04 0.93-1.17 0.471
Roof material: Iron sheet - - -
Proportion of nets being LLINs 0.99 0.98-1.00 0.004
Toilet facilities: Pit latrine 0.37 0.12-1.16 0.088
Robust standard errors were applied to the final models.
Reference sex is male; reference age < 10 years; reference roof material grass thatch; reference toilet facility none.
1 Universal net coverage defined as households with one or more net for every two people;
2 Baseline village prevalence of P. falciparum among ≥ 5 years is included in P. falciparum models, while baseline village mf prevalence among ≥ 5 years is
included in W. bancrofti models.
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tion, but universal coverage in a household was protec-
tive, perhaps represents the importance of consistent
and long-term use of mosquito nets. This may also be
related to the known inefficient transmission of W. ban-
crofti, with humans requiring multiple exposures before
a productive infection develops.
The increase in mosquito biting rate between 2008
and 2010 indicates an increased vector population at the
s t u d ys i t ea tt h et i m eo ft h es u r v e y ,s u g g e s t i n gt h a t
LLINs afforded little protection. However, it should be
noted that biting rate was not measured directly through
human landing catches in this instance, but approxi-
mated during each survey using catches from CDC light
traps. A variation in the timing of seasonal rains each
year, and resultant changes in the peak of the mosquito
population, is likely to have been a major contributor to
the variation in mosquito population and biting rates
observed between years. In the absence of monthly mos-
quito collection data this interpretation could, however,
not be confirmed as we were unable to tell whether
mosquito collections were always made at the same
point in the annual population fluctuation. An alterna-
tive interpretation may be that a reduction in W. ban-
crofti transmission may have led to increased mosquito
survival, as a result of facilitation [18], in turn increasing
the overall mosquito population. However, a recent
meta analysis of data documenting the effects of W.
bancrofti infection on various mosquito species found
limited evidence for any association [41], and it is there-
fore considered unlikely that the reduction in W. ban-
crofti transmission at the study site directly related to
the increased mosquito population and biting rate.
While the major indicator of effectiveness of LLINs in
LF prevention is a reduction in filarial vector density
[20], scale up in LLIN use has also been shown to
reduce vector lifespan [42], which would consequently
reduce the number of mosquitoes which live long
enough for ingested mf to develop into infectious L3
stages, and would therefore reduce transmission. How-
ever, in the current study mosquito age was not evalu-
ated, and should the increase in vector population
indicated by these data hold true throughout the year,
rather than for a single time point, then it would sub-
stantiate the suggestion that LLINs have contributed lit-
tle to the reduction in W. bancrofti transmission.
A key strategy for defining the extent of current trans-
mission is through entomological indicators. While dis-
section and examination of mosquitoes for presence of
W. bancrofti larvae has long been considered the gold
standard technique, molecular xenomonitoring has a
number of advantages relevant to the LF elimination
programme. We found that once W. bancrofti transmis-
sion had declined to very low levels, dissection of the
large number of mosquitoes required to accurately
determine transmission is laborious and time consum-
ing. Resources permitting, investigators planning to con-
duct similar studies may choose to employ polymerase
chain reaction (PCR) methods, which can reliably detect
W. bancrofti from pooled samples of mosquitoes [43]. A
modification of this PCR technique has been described
that is able to detect the human-infective L3 larval
stages in mosquitoes [44,45]. However, PCR does not
allow for quantification of the intensity of infection and
requires specialised equipment and highly trained staff.
Nevertheless, PCR appears to be a useful method for
validation purposes in the elimination programme.
T h ec u r r e n ts t u d yh a dan u m ber of limitations. Most
importantly it was not designed to determine the indivi-
dual contributions of MDA and LLINs to the reduction
in LF transmission. The baseline survey in July 2007 was
implemented after MDA had already been conducted
three times in the study area, in 2002, 2004 and 2005.
Experience from other settings has shown that a single
MDA round can reduce mf prevalence in the population
by anything from 21% to 76%, depending on the trans-
mission setting, while in years when no MDA is con-
ducted a resurgence in mf prevalence may be observed
[35,37,46]. It is therefore difficult to determine if the mf
rates in 2007 are the true baseline for this setting, and
to what extent the previous rounds of MDA and the
two-year gap during which no MDA took place had
reduced W. bancrofti infection in the human population.
Furthermore, as experienced by other investigators, diffi-
culties were encountered in determining the number
MDA rounds that study participants had received [47].
Multivariate modelling was therefore not able to control
for the number of times individuals had received alben-
dazole plus ivermectin. It is possible that the observed
protective effect of universal net coverage against W.
bancrofti may have been confounded by those house-
holds and individuals being more health conscious and
therefore more likely to have participated in multiple
rounds of MDA.
The change in sampling strategy between baseline and
final follow-up surveys presents a further limitation of
this study. Baseline results found a lower than expected
mf prevalence in the population, particularly in children
under five years. In order to maximise the statistical
power of the comparison in mf rates between baseline
and follow-up and identify any recent change in W. ban-
crofti transmission, it was decided to increase the num-
ber of children under five tested in the 2010 survey.
While this change in sampling means that crude popula-
tion prevalence is not comparable between 2007 and
2010 data, age stratification to < 5 and ≥ 5, as well as
calculation of age-adjusted prevalence has overcome
this. Furthermore, use of ICTs as a primary diagnostic
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Page 11 of 13tool in 2010 allowed evaluation of W. bancrofti antigen
prevalence, which is less affected by MDA than mf pre-
valence since ivermectin and albendazole have limited
macrofilaricidal effect [48,49]. As transmission reduces it
is antigen prevalence detected by ICTs, not mf detected
by microscopy, that will indicate the continued presence
of adult worms in the human population, which could
lead to resurgence in transmission after MDA has
ceased.
Conclusions
This study has documented a sharp decline in W. ban-
crofti infection in humans, as well as reduction in trans-
mission potential by the Anopheles vector, in a
previously highly LF endemic area of Uganda.
The study area had received multiple rounds of MDA
with albendazole and ivermectin, and seen a large
increase in LLIN ownership and use. While statistical
modelling did indicate some protective effect of univer-
sal coverage of LLINs against W. bancrofti,i nt h i ss e t -
ting it was not possible to determine the effect of MDA
and LLIN use against transmission individually. Further-
more, the impact of LLINs on transmission in mosqui-
toes is equivocal due to the observed increase in vector
densities and monthly biting rates, despite a reduction a
W. bancrofti prevalence in mosquitoes. The potential
additional benefit of mosquito nets against LF should be
taken into account in the current scale up of LLIN cov-
erage for malaria prevention, as high population cover-
age of nets in areas where both malaria and LF are
transmitted by anopheline mosquitoes could yield
enhanced cost-effectiveness.
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